Factors Associated With Recurrence After Adjuvant Gemcitabine and Nab‐Paclitaxel in Patients With Resected Pancreatic Ductal Adenocarcinoma
Cancer Medicine · 2026-11 · 15 (11)
DOI: 10.1002/cam4.72491 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 05.11.2026. Verfasst von Tao Xia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Paclitaxel, Deoxycytidine, Pancreatic Neoplasms. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Key Science and Technology Project of Zhejiang Province.
Abstract (Originalsprache)
Background
Pancreatic ductal adenocarcinoma (PDAC) carries a poor prognosis despite curative‐intent resection and adjuvant therapy. Gemcitabine plus nab‐paclitaxel (Gem‐NAP) has become a standard adjuvant regimen for PDAC, yet recurrence rates remain high. This study aimed to identify clinical and pathological factors associated with recurrence and survival in patients receiving adjuvant Gem‐NAP following PDAC resection.
Methods
We retrospectively identified 210 patients with resected PDAC who received adjuvant gemcitabine and nab‐paclitaxel at a single institution between May 2017 and October 2024. Clinicopathological characteristics, recurrence patterns, disease‐free survival (DFS), and overall survival (OS) were analyzed. Univariate and multivariate models were utilized to identify independent predictors of recurrence and survival.
Results
In total, 132 patients (62.9%) experienced recurrence, with a median DFS of 21.0 months (95% CI: 16.7–25.3) and a median OS of 39.0 months (95% CI: 32.7–45.3). Local recurrence (28.6%) and liver metastasis (24.8%) were the most common recurrence sites. Multivariable analysis revealed that preoperative CA19‐9 > 37 U/mL (OR: 2.28; 95% CI: 1.19–4.34; p = 0.01) and a lymph node ratio (LNR) > 0.14 (OR: 2.98; 95% CI: 1.19–7.47; p = 0.02) were significantly associated with recurrence. Independent predictors of worse DFS included elevated preoperative CA19‐9 (> 37 U/mL) (HR: 1.59; 95% CI: 1.04–2.43; p = 0.03), LNR > 0.14 (HR: 1.88; 95% CI: 1.23–2.89; p < 0.01), R1 resection (HR: 2.71; 95% CI: 1.36–5.38; p < 0.01), and lymphovascular invasion (LVI) (HR: 1.59; 95% CI: 1.09–2.30; p = 0.02). For OS, the independent predictors were R1 resection (HR: 3.00; 95% CI: 1.45–6.22; p < 0.01), LVI positivity (HR: 1.55; 95% CI: 1.03–2.34; p = 0.04), and LNR > 0.14 (HR: 1.76; 95% CI: 1.11–2.80; p = 0.02).
Conclusions
Recurrence after adjuvant gemcitabine and nab‐paclitaxel in patients with resected pancreatic cancer remains common. A high lymph node ratio, R1 resection, and lymphovascular invasion were powerful independent predictors of both poor DFS and OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China.
Förderung
- National Natural Science Foundation of China
- Key Science and Technology Project of Zhejiang Province
Zitieren
APA
Xia, T., Cheng, C., Meng, Y., Huang, H., Li, D., Zhu, R., Qiu, C., & Hua, Y. (2026). Factors Associated With Recurrence After Adjuvant Gemcitabine and Nab‐Paclitaxel in Patients With Resected Pancreatic Ductal Adenocarcinoma. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72491
Vancouver
Xia T, Cheng C, Meng Y, Huang H, Li D, Zhu R, et al. Factors Associated With Recurrence After Adjuvant Gemcitabine and Nab‐Paclitaxel in Patients With Resected Pancreatic Ductal Adenocarcinoma. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72491
BibTeX
@article{Xia2026,
author = {Xia, Tao and Cheng, Chi and Meng, Yudi and Huang, Hao and Li, Duo and Zhu, Renfan and Qiu, Chengcong and Hua, Yongfei},
title = {Factors Associated With Recurrence After Adjuvant Gemcitabine and Nab‐Paclitaxel in Patients With Resected Pancreatic Ductal Adenocarcinoma},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/cam4.72491}
}
EUVIMED